معرفی
Thomas Vogl serves as Assistant Professor and Group Leader at the Center for Cancer Research, Medical University of Vienna, where he investigates the critical interplay between the immune system and gut microbiome in cancer development and therapy response. His multidisciplinary team integrates molecular biology, biochemistry, and bioinformatics to analyze systemic antibody responses against microbial components, with particular focus on how microbiome composition influences immunotherapy efficacy and cancer progression.
Dr. Vogl's research program centers on antibody-microbiome interactions in oncology, exploring how microbial factors modulate immune responses to tumors. His work reveals connections between gut microbiota diversity and therapeutic outcomes in colorectal cancer, while identifying specific antibody signatures associated with inflammatory conditions like Crohn's disease and chronic fatigue syndrome (ME/CFS). This research bridges computational immunology and clinical oncology to develop microbiome-based diagnostics and therapeutic strategies.
His publication record demonstrates consistent innovation in systems immunology, with recent work establishing links between microbiome-derived flagellins and immune dysregulation across multiple diseases. Key trends include the development of high-throughput methods for antibody epitope mapping and the discovery of cross-reactive immune responses with implications for cancer and infectious disease diagnostics.
Scientific recognition includes:
- ERC Starting Grant (2022) for "EarlyMicroAbs" project
- Nature Research Global Grant for Gut Health (2023/24)
- Elisabeth Lutz Prize of the Austrian Academy of Sciences (2024)
Dr. Vogl currently supervises five PhD students and leads a research group comprising postdoctoral scientists and technical staff. His major funding includes coordination of the €8.4 million EU Horizon Health consortium "ID-DarkMatter-NCD" and partnership in the ZonMW ME/CFS Lines consortium, supporting translational research into microbiome-immune interactions. He actively promotes equitable research environments as a contributor to the SAFE Labs initiative, having co-authored the SAFE Labs Handbook and associated white paper to advance laboratory inclusivity and fairness.
